High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1079-1082

  Baraliakos, X ^a   Baerlecken, N ^b   Witte, T ^b   Heldmann, F ^a   Braun, J ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; HLA B27 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AXIAL SPONDYLARTHRITIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS;

ANKYLOSING SPONDYLITIS; CHEMOKINES; INFLAMMATION;

ADULT; AGED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-B27 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 84899923622     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202177     Document Type: Article

References (36)

1. Haglund E, Bremander AB, Petersson IF, et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis 2011;70: 943-8.
2. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41: 58-67. (Pubitemid 28041923)
3. Trontzas P, Andrianakos A, Miyakis S, et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol 2005;24: 583-9. (Pubitemid 41644325)
4. De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol 2007;36: 14-21. (Pubitemid 46572904)
5. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68: 777-83.
6. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009;60: 717-27.
7. Poddubnyy D, Vahldiek J, Spiller I, et al. Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 2011;38: 2452-60.
8. Dincer U, Cakar E, Kiralp MZ, et al. Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 2008;27: 457-62. (Pubitemid 351404300)
9. Bennett AN, Rehman A, Hensor EM, et al. The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 2010;69: 891-4.
10. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? Arthritis Rheum 2005;52: 1000-8. (Pubitemid 40530105)
11. Lotteau V, Teyton L, Peleraux A, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348: 600-5. (Pubitemid 120015113)
12. Arneson LS, Miller J. The chondroitin sulfate form of invariant chain trimerizes with conventional invariant chain and these complexes are rapidly transported from the trans-Golgi network to the cell surface. Biochem J 2007;406: 97-103. (Pubitemid 47264739)
13. Matza D, Wolstein O, Dikstein R, et al. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program. J Biol Chem 2001;276: 27203-06.
14. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107: 4807-16. (Pubitemid 43882632)
15. Baerlecken N, Nothdorf S, Stummvoll G, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 2013. doi: 10.1136/annrheumdis-2012-202208
16. Seager K, Bashir HV, Geczy AF, et al. Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis. Nature 1979;277: 68-70. (Pubitemid 9078587)
17. Georgopoulos K, Dick WC, Goodacre JA, et al. A reinvestigation of the cross-reactivity between Klebsiella and HLA-B27 in the aetiology of ankylosing spondylitis. Clin Exp Immunol 1985;62: 662-71. (Pubitemid 16250485)
18. Chou CL, Wu MJ, Yu CL, et al. Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis. Clin Rheumatol 2010;29: 875-81.
19. Duftner C, Dejaco C, Klauser A, et al. High positive predictive value of specific antibodies cross-reacting with a 28-kDa Drosophila antigen for diagnosis of ankylosing spondylitis. Rheumatology (Oxford) 2006;45: 38-42. (Pubitemid 43033872)
20. Wang M, Li X, Chen J, et al. Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique. Rheumatol Int 2011;31: 1009-16.
21. Wright C, Sibani S, Trudgian D, et al. Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics 2012;11:M9 00384.
22. Heldmann F, Brandt J, van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29: 672-80.
23. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
24. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21: 2281-5.
25. Khan MA, Mathieu A, Sorrentino R, et al. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev 2007;6: 183-9. (Pubitemid 46187337)
26. Seipp MT, Erali M, Wies RL, et al. HLA-B27 typing: evaluation of an allele-specific PCR melting assay and two flow cytometric antigen assays. Cytometry B Clin Cytom 2005;63: 10-15. (Pubitemid 40096839)
27. Khan MA. HLA-B27 polymorphism and association with disease. J Rheumatol 2000;27: 1110-14.
28. Khan MA, Khan MK. Diagnostic value of HLA-B27 testing ankylosing spondylitis and Reiter's syndrome. Ann Intern Med 1982;96: 70-6. (Pubitemid 12205525)
29. Chung HY, Machado P, van der Heijde D, et al. HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis 2011;70: 1930-6.
30. Stone MA, Pomeroy E, Keat A, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology (Oxford) 2008;47: 1213-18. (Pubitemid 352038229)
31. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58: 1981-91. (Pubitemid 351988090)
32. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38: 499-505.
33. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59: 135-40. (Pubitemid 30305612)
34. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006;54: 2845-51. (Pubitemid 44497763)
35. Song IH, Heldmann F, Rudwaleit M, et al. Major clinical response of rituximab in active TNF-blocker naive patients with ankylosing spondylitis but not in TNF-blocker-failure patients-an open label clinical trial. Ann Rheum Dis 2009;68 (Suppl.3):74.
36. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62: 1290-7.